因塞特 INCY 深 沪
等待开盘 10-31 09:30:00 美东时间
93.32
+3.140
+3.48%
华盛通- 最 高94.62
- 今 开91.34
- 成交量 142.75万股
- 最 低 91.19
- 昨 收 90.18
- 总市值 181.97亿
- 52周最高 94.62
- 市盈率 静 602.45
- 换手率 0.73%
- 52周最低 53.56
- 委 比 -54.09%
- 总股本 1.95亿
- 历史最高 153.15
- 量 比 0.48
- 振 幅 3.80%
- 历史最低 11.76
- 每 手 1
- 风险率 8.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多McKesson declares $0.82 dividend
McKesson (MCK) declares $0.82/share quarterly dividend, in line with previous. Forward yield 0.41% Payable Jan. 2; for shareholders of record Dec. 1; ex-div Dec. 1. See MCK Dividend Scorecard, Yield C...
10-30 20:07
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.
10-29 02:44
DexCom falls as Hunterbrook releases new short report
DexCom (NASDAQ:DXCM) dropped 3% after Hunterbrook released a new short report, after targeting the company previously. Hunterbrook Capital disclosed that it's short shares of DexCom. DexCom didn't i...
10-29 01:35
华尔街顶级分析师最新评级报告：华纳兄弟探索频道获上调评级
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总如下。以下是由 The Fly 整理的今日投资者需重点关注的评级动态。 五大评级上调案例： 阿格斯...
10-28 22:11
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
首次！诺华 CDK2 抑制剂在国内申报临床
（来源：求实药社） 10 月 27 日，CDE 官网显示，诺华的 CDK2 抑制剂 ECI830 临床试验申请获受理。这是国内第 4 款申报临床的 CDK2 抑...
10-28 12:08
Incyte’s Clinical Study Update: Advancing Multiple Myeloma Treatment
Incyte (($INCY)) announced an update on their ongoing clinical study. Study Ove...
10-28 00:53
Incyte Partners With Enable Injections to Develop Easier At-Home Treatments for Rare Blood Cancers
Incyte (NASDAQ:INCY) and Enable Injections, Inc. ("Enable") today announced a new partnership to develop and commercialize specific assets in Incyte's portfolio, including its investigational, first-in-class mutant
10-27 19:35
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to FDA-approved T Cell Engagers (TCE) for B cell depletion with minimal cytokine release, highlighting safer deep B cell depletion. It is the first pan-gamma delta T cell engager designed to expand multiple gamma delta T cell subsets for efficient target elimination. INB-619 achieved robust gamma delta T cell expansion and complete B cell depletion in both healthy donor and SLE samples. Unlike conventional...
10-27 12:00
